Intratumoral Immunotherapy for Early-stage Solid Tumors

Area of Science:

• Oncology
• Immunology
• Drug Delivery

Background:

• Immunotherapy has shown significant benefits in advanced cancers, leading to interest in its use for earlier-stage solid tumors.
• Systemic immunotherapy can cause severe side effects and limit combination therapies.
• Intratumoral delivery offers a strategy to maximize immunotherapy's benefits while reducing toxicity.

Purpose of the Study:

• To review the potential of intratumoral neoadjuvant immunotherapy.
• To discuss drug delivery technologies and combination strategies.
• To summarize preclinical and clinical evidence for intratumoral immunotherapy.

Main Methods:

• Review of current preclinical and clinical research on intratumoral immunotherapy.
• Discussion of drug delivery technologies for local immune agent administration.
• Analysis of ongoing neoadjuvant clinical trials.

Main Results:

• Intratumoral delivery primes local tumor-specific immunity, potentially leading to systemic responses.
• Over 20 neoadjuvant clinical trials are investigating various intratumoral immune stimulatory agents and combinations.
• Promising drug delivery technologies and combination strategies are emerging.

Conclusions:

• Intratumoral neoadjuvant immunotherapy is a promising strategy to improve efficacy and reduce toxicity in cancer treatment.
• Optimal timing and local delivery are crucial for safety and effectiveness.
• This approach holds potential for integration into routine oncologic care.